JP2021501587A - Ｃｄ３８指向性キメラ抗原受容体構築物 - Google Patents

Ｃｄ３８指向性キメラ抗原受容体構築物 Download PDF

Info

Publication number
JP2021501587A
JP2021501587A JP2020524366A JP2020524366A JP2021501587A JP 2021501587 A JP2021501587 A JP 2021501587A JP 2020524366 A JP2020524366 A JP 2020524366A JP 2020524366 A JP2020524366 A JP 2020524366A JP 2021501587 A JP2021501587 A JP 2021501587A
Authority
JP
Japan
Prior art keywords
acid sequence
amino acid
car
domain
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020524366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501587A5 (enExample
Inventor
ヤンリャン ジャン，
ヤンリャン ジャン，
ヘユエ ジョウ，
ヘユエ ジョウ，
チアンジョン マ，
チアンジョン マ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorrento Therapeutics Inc
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of JP2021501587A publication Critical patent/JP2021501587A/ja
Publication of JP2021501587A5 publication Critical patent/JP2021501587A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4222—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
JP2020524366A 2017-11-03 2018-11-02 Ｃｄ３８指向性キメラ抗原受容体構築物 Pending JP2021501587A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762581466P 2017-11-03 2017-11-03
US62/581,466 2017-11-03
PCT/IB2018/058642 WO2019087151A1 (en) 2017-11-03 2018-11-02 Cd38-directed chimeric antigen receptor constructs

Publications (2)

Publication Number Publication Date
JP2021501587A true JP2021501587A (ja) 2021-01-21
JP2021501587A5 JP2021501587A5 (enExample) 2021-12-09

Family

ID=64277751

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020524366A Pending JP2021501587A (ja) 2017-11-03 2018-11-02 Ｃｄ３８指向性キメラ抗原受容体構築物

Country Status (8)

Country Link
US (1) US11760806B2 (enExample)
EP (1) EP3704156A1 (enExample)
JP (1) JP2021501587A (enExample)
KR (1) KR20200076732A (enExample)
CN (1) CN111542545A (enExample)
AU (1) AU2018362014A1 (enExample)
CA (1) CA3080109A1 (enExample)
WO (1) WO2019087151A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019173837A1 (en) 2018-03-09 2019-09-12 Sorrento Therapeutics, Inc. Dimeric antigen receptors (dar)
CA3103114A1 (en) * 2018-06-20 2019-12-26 Sorrento Therapeutics, Inc. Variant antibody that binds cd38
CA3126735A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
JP2022538461A (ja) * 2019-07-01 2022-09-02 ソレント・セラピューティクス・インコーポレイテッド Ｃｄ３８およびｃｄ３に結合するヘテロ二量体抗体
WO2021009263A1 (en) * 2019-07-16 2021-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity for cd38 and uses thereof
WO2021016621A1 (en) 2019-07-25 2021-01-28 Celularity Inc. Populations of natural killer cells comprising a cd38 chimeric antigen receptor
EP4225799A4 (en) * 2020-10-12 2024-11-20 Sorrento Therapeutics, Inc. CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS
CN113663061A (zh) * 2021-08-04 2021-11-19 上海优卡迪生物医药科技有限公司 Cd38在制备car-t药物中的应用
CN113893338A (zh) * 2021-11-04 2022-01-07 苏州大学附属第一医院 Cd38 car-t细胞在慢性粒细胞白血病急髓变中的应用
AU2023373900A1 (en) * 2022-11-02 2025-05-15 Medisix Therapeutics, Inc. Methods and systems for production of engineered t-cells
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105802975A (zh) * 2014-12-31 2016-07-27 浙江大学 靶向her2阳性肿瘤的细胞制备物及其用途
WO2016164669A2 (en) * 2015-04-08 2016-10-13 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd38
WO2016168493A1 (en) * 2015-04-15 2016-10-20 Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center Hepatic arterial infusion of car-t cells
WO2017025323A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
JP2017506636A (ja) * 2014-02-14 2017-03-09 セレクティスＣｅｌｌｅｃｔｉｓ 免疫細胞と病的細胞の両方に存在する抗原を標的とするように操作された、免疫療法のための細胞
WO2017070654A1 (en) * 2015-10-23 2017-04-27 Sorrento Therapeutics, Inc. Programmable universal cell receptors and methods of using the same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0651805B1 (en) * 1992-07-17 2006-12-13 Dana Farber Cancer Institute Method of intracellular binding of target molecules
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EA015584B1 (ru) 2005-03-23 2011-10-31 Генмаб А/С Антитело к cd38 человека и его применение
JP5362359B2 (ja) 2005-10-12 2013-12-11 モルフォシス アーゲー ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング
ES2911246T3 (es) 2009-11-03 2022-05-18 Hope City Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
US9212229B2 (en) 2010-09-08 2015-12-15 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
EP3063173B1 (en) 2013-10-31 2020-07-29 Sanofi Specific anti-cd38 antibodies for treating human cancers
EP3172228B1 (en) 2014-07-25 2019-02-27 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
WO2016044811A1 (en) * 2014-09-19 2016-03-24 City Of Hope COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Rα2
CN107249604A (zh) * 2014-12-31 2017-10-13 人类起源公司 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
GB201518817D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Cell
KR102664453B1 (ko) 2017-02-21 2024-05-10 주식회사 유틸렉스 Hla-dr car-t 조성물 및 그를 제조하고 사용하는 방법
WO2019173837A1 (en) * 2018-03-09 2019-09-12 Sorrento Therapeutics, Inc. Dimeric antigen receptors (dar)
AU2019310430A1 (en) * 2018-07-23 2021-02-25 Magenta Therapeutics, Inc. Use of an anti-CD2 antibody drug conjugate (ADC) in allogeneic cell therapy
AU2019312200B2 (en) * 2018-07-23 2024-11-14 Heidelberg Pharma Research Gmbh Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017506636A (ja) * 2014-02-14 2017-03-09 セレクティスＣｅｌｌｅｃｔｉｓ 免疫細胞と病的細胞の両方に存在する抗原を標的とするように操作された、免疫療法のための細胞
CN105802975A (zh) * 2014-12-31 2016-07-27 浙江大学 靶向her2阳性肿瘤的细胞制备物及其用途
WO2016164669A2 (en) * 2015-04-08 2016-10-13 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd38
WO2016168493A1 (en) * 2015-04-15 2016-10-20 Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center Hepatic arterial infusion of car-t cells
WO2017025323A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
WO2017070654A1 (en) * 2015-10-23 2017-04-27 Sorrento Therapeutics, Inc. Programmable universal cell receptors and methods of using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOLECULAR THERAPY, AUG 2017, VOL.25, NO.8, PP.1946-1958, JPN6022043627, ISSN: 0004977554 *

Also Published As

Publication number Publication date
EP3704156A1 (en) 2020-09-09
WO2019087151A1 (en) 2019-05-09
CN111542545A (zh) 2020-08-14
US20190135937A1 (en) 2019-05-09
CA3080109A1 (en) 2019-05-09
US11760806B2 (en) 2023-09-19
AU2018362014A1 (en) 2020-05-28
KR20200076732A (ko) 2020-06-29

Similar Documents

Publication Publication Date Title
US11760806B2 (en) CD-38 directed chimeric antigen receptor constructs
AU2021307614B2 (en) Engineered immune cell for allotransplantation
JP2024518011A (ja) 多様な免疫細胞のための単鎖および多鎖合成抗原受容体
CN116063550A (zh) 靶向nk激活性受体的嵌合抗原受体
TW202000691A (zh) 嵌合跨膜蛋白及其用途
US20230242661A1 (en) Engineered immune cell expressing nk inhibitory molecule and use thereof
WO2021030153A2 (en) Engineered t cell receptors and uses thereof
JP7723420B2 (ja) Ｂ細胞標的化並列ＣＡＲ（ｐＣＡＲ）治療的薬剤
US20240082306A1 (en) Novel chimeric antigen receptor and use thereof
EP4194472A1 (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof
KR20250133399A (ko) 유전자 전달 및 합성 및 면역 수용체의 활성을 제어하기 위한 방법 및 조성물
CN117683139A (zh) 组成型嵌合细胞因子受体及表达其的免疫细胞及应用
CN117202921A (zh) 用于多种免疫细胞的单链和多链合成抗原受体
TW202430565A (zh) 包含與il18組合之新穎cd19結合體之car-t構築體及其使用方法
KR20230159366A (ko) 양방향 신호전달 활성을 갖는 키메라 막관통 단백질
US20240261330A1 (en) CD19-Directed Chimeric Antigen Receptor Constructs
WO2024179620A2 (zh) 耐免疫排斥的工程化细胞
WO2025214498A1 (en) Composition and method of cellular immunotherapy
US12286465B2 (en) Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
HK40030299A (en) Cd38-directed chimeric antigen receptor constructs
HK40086008A (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230131